Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Cohance Lifesciences
Mid Cap•1,212 Employees•IPO 2020
Current Price
₹291.70
-3.9 (-1.32%)Updated
Today's Range
288.6
₹291.70
312.9
52 Week Range
52W Low₹266.70
52W High₹1121.15
₹291.70
Downside9.37%
Upside284.35%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹11,771.59 Cr
Market Cap
Total market value of companyP/E Ratio
58.36
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
8.88
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹5.80
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
4.23%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
14.90%
ROCE
Return on Capital Employed. >15% is goodNet Margin
9.83%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-3.37%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
7.51%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
12.60%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-27.50%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.16
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹66.65
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
57.50%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •The company maintains a very healthy debt-to-equity ratio of 0.16, indicating strong financial stability and low reliance on borrowed capital, which is positive for long-term sustainability.
- •Cohance Lifesciences demonstrates a strong operating profit margin (OPM) of 28.80%, highlighting efficient cost management and healthy core business profitability.
Weaknesses
6 points- •With a P/E ratio of 86.10, the stock appears significantly overvalued compared to the industry average and most peers, suggesting high investor expectations that may be difficult to sustain.
- •The company experienced a substantial -27.50% decline in quarterly profit, raising concerns about recent operational challenges or increased costs impacting profitability.
Opportunities
4 points- •The broader Pharmaceuticals sector commands a high P/E of 147.31, suggesting strong investor appetite and growth potential within the industry that Cohance can leverage.
- •Being in the Pharmaceuticals and Healthcare sector, Cohance is positioned to benefit from increasing global demand for healthcare products, R&D advancements, and market expansion.
Threats
5 points- •Cohance faces stiff competition from larger, more profitable peers like Sun Pharma and Zydus Lifesciences, which could limit its market share and pricing power.
- •The pharmaceutical industry is highly regulated; adverse changes in drug pricing policies, approvals, or manufacturing standards could significantly impact operations.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Jusmiral Holdings Limited | 09 May 2025 | 12 May 2025 | 12.65 Cr | 12.65 Cr | ₹1 | BUY |
Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri | 09 May 2025 | 12 May 2025 | 7.13 L | 7.13 L | ₹1 | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹355.47 | +₹63.77 | +21.86% |
| R3 | ₹331.17 | +₹39.47 | +13.53% |
| R2 | ₹322.03 | +₹30.33 | +10.40% |
| R1 | ₹306.87 | +₹15.17 | +5.20% |
| PIVOT | ₹297.73 | 6.03 | 2.07% |
| CURRENT | ₹291.70 | - | - |
| S1 | ₹233.97 | -₹57.73 | -19.79% |
| S2 | ₹258.27 | -₹33.43 | -11.46% |
| S3 | ₹273.43 | -₹18.27 | -6.26% |
| S4 | ₹282.57 | -₹9.13 | -3.13% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-2.9% vs avg
1.76M
(11 Mar 2026)Delivery %-5.6% vs avg
31.6%
(11 Mar 2026)Avg Volume (20D)20-day average
1.81M
(11 Feb - 11 Mar)Avg Delivery %Trend ↓
37.2%
(11 Feb - 11 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Procter & Gamble Health Ltd
158.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Aether Industries Ltd |
 Ajanta Pharma Ltd |
 Alivus Life Sciences Ltd |
 Alembic Pharmaceuticals Ltd |
 Astrazeneca Pharma India Ltd |
 Caplin Point Laboratories Ltd |
 Concord Biotech Ltd |
 Emcure Pharmaceuticals Ltd |
 Gland Pharma Ltd |
 Glaxosmithkline Pharmaceuticals Ltd |
 Glenmark Pharmaceuticals Ltd |
 Granules India Ltd |
 Ipca Laboratories Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 Pfizer Ltd |
 Procter & Gamble Health Ltd |
 Piramal Pharma Ltd |
 |
 Sanofi India Ltd |
 Sanofi Consumer Healthcare India Ltd |
 Sun Pharmaceutical Industries Ltd |
About
Cohance Lifesciences Ltd
Cohance Lifesciences Limited is an Indian contract development and manufacturing organization (CDMO) specializing in the pharmaceutical industry. Their core business revolves around providing comprehensive services throughout the entire drug development and manufacturing process, from the initial stages of creating intermediate compounds and active pharmaceutical ingredients (APIs) to the final production of finished dosage formulations (FDFs).
A significant portion of Cohance's business is centered around its CDMO services. This encompasses offering flexible and customized solutions designed to meet the unique and often complex development and manufacturing requirements of its clients. They cater to companies needing assistance with various aspects of drug production, allowing for tailored approaches to challenges encountered during the drug lifecycle.
Beyond CDMO services, Cohance produces and supplies APIs and FDFs for a wide range of pharmaceutical applications. This direct manufacturing capability complements their CDMO services, offering clients a complete spectrum of pharmaceutical production capabilities, from basic building blocks to final consumer-ready products. Their API offerings extend beyond pharmaceuticals; they also manufacture specialty chemicals, such as those used in the electronics industry.
Supporting their core manufacturing and development functions, Cohance provides a suite of analytical, clinical, and research services. These services likely support internal processes as well as offer additional services to clients, furthering their role as a comprehensive partner for pharmaceutical development. The integrated nature of these services underlines their commitment to a holistic approach in servicing the pharmaceutical industry.
Established in 1989 and based in Hyderabad, India, Cohance (formerly Suven Pharmaceuticals Limited) is a subsidiary of Berhyanda Limited. The company's long history and presence in India's pharmaceutical sector positions it as a significant player in the global CDMO landscape. Their diverse offerings and commitment to customized solutions underscore their efforts to cater to the evolving needs of the pharmaceutical market.
COMPANY FACTS - COHANCE
Registered Address
202, A-Wing, Galaxy Towers, Plot No-1, Hyderabad Knowledge City,, TSIIC, Raidurg, Serilingampally,
Rangareddi
TELANGANA
IN
Tel: 914023549414
Website:https://www.cohance.com/
Investor Relations:http://www.suvenpharm.com/index.php/investors
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,212
IPO Date: 09/03/2020
MANAGEMENT - COHANCE
Mr. Vivek Sharma
Executive Chairman of the Board
Mr. Yann D'herve
Chief Executive Officer
Mr. Himanshu Agarwal
Chief Financial Officer
Mr. Kundan Jha
Compliance Officer, Company Secretary, Head- Legal
Dr. Vetukuri Venkata Prasada Raju
Managing Director, Executive Director
Ms. Shweta Jalan
Non-Executive Director
Mr. Vinod Padikkal
Non-Executive Director
Mr. Pankaj Patwari
Non-Executive Director
Mr. Kumarapuram Ananthakrishnan
Non-Executive Independent Director
Ms. Matangi Gowrishankar
Non-Executive Independent Director
Mr. Jai Krishnan
Non-Executive Independent Director
Mr. Udhyavara Bhadya Rao
Non-Executive Independent Director
Investor Questions Answered
Cohance Lifesciences Ltd (COHANCE) Stock FAQs
Get answers to the most common questions about Cohance Lifesciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Cohance Lifesciences Ltd (COHANCE) is ₹291.7. Today, the stock has declined by ₹3.90 (1.32%), trading in a range of ₹288.6 to ₹312.9. The stock opened at ₹295.6 with a trading volume of 17,58,538 shares.
Cohance Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,771.59 crores, P/E ratio of 58.36, ROE of 4.23%, and ROCE of 14.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Cohance Lifesciences Ltd (COHANCE) is ₹1,121.15, while the 52-week low is ₹266.7. Currently trading at ₹291.7, the stock is 2.9% away from its 52-week low and 74.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Cohance Lifesciences Ltd stock at ₹291.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 58.36 and P/B ratio of N/A. Today's performance shows a loss of 1.32%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Cohance Lifesciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹291.7, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Cohance Lifesciences Ltd's key financial metrics include: P/E Ratio: 58.36, P/B Ratio: N/A, ROE: 4.23%, ROCE: 14.90%, Dividend Yield: 0.00%, EPS: ₹5.80, Book Value: ₹66.65, Debt-to-Equity: 0.16, and Current Ratio: N/A. The company's market cap stands at ₹11,771.59 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Cohance Lifesciences Ltd stock opened at ₹295.6 and is currently trading at ₹291.7, showing a decline of ₹3.90 (1.32%). The intraday high is ₹312.9 and low is ₹288.6. The trading volume stands at 17,58,538 shares, indicating strong market participation today.
Cohance Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 58.36, which means investors are willing to pay ₹58.36 for every ₹1 of earnings. With an EPS of ₹5.80, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Cohance Lifesciences Ltd has a market capitalization of ₹11,771.59 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹291.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Cohance Lifesciences Ltd has a book value of ₹66.65 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹291.7, which is 337.7% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Cohance Lifesciences Ltd has a Return on Equity (ROE) of 4.23% and Return on Capital Employed (ROCE) of 14.90%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Cohance Lifesciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Cohance Lifesciences Ltd has a debt-to-equity ratio of 0.16, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Cohance Lifesciences Ltd has an Earnings Per Share (EPS) of ₹5.80, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹291.7 and P/E ratio of 58.36, investors are paying 58.36 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Cohance Lifesciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Cohance Lifesciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Cohance Lifesciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (58.36), ROE (4.23%), debt-to-equity (0.16), and growth rates. 2) Technical Analysis - Check 52-week range (₹266.70 - ₹1121.15), moving averages, and chart patterns. 3) Valuation - Compare current price (₹291.70) with book value (₹66.65) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Cohance Lifesciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹291.7 is 29070x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Cohance Lifesciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹266.70 - ₹1121.15). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.16 indicates leverage. 4) Liquidity Risk - Based on trading volume of 17,58,538 shares. 5) Valuation Risk - P/E of 58.36 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Cohance Lifesciences Ltd operates in the industry with key metrics: P/E ratio of 58.36, ROE of 4.23%, market cap of ₹11,771.59 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.16), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Cohance Lifesciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹291.7, with a 52-week range of ₹266.70 to ₹1121.15. Based on fundamentals like P/E (58.36), ROE (4.23%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Cohance Lifesciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹291.70. 2) Fundamental Deterioration - Declining ROE (currently 4.23%), increasing debt (D/E: 0.16), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Cohance Lifesciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu